Metropolis Healthcare (METROPOLIS) Q2 26/27 earnings summary

Executive summary

• H1 FY27 revenue rose 16.2% YoY to ₹9,470.36 million, ahead of guidance; reported EBITDA grew 25.3% to ₹248.2 crore and PAT rose 34.9% to ₹132.4 crore.

• Q2 growth was broad-based and volume-led, supported by richer mix, channel and regional breadth, and expansion in TruHealth and Specialty.

Financial highlights

• Q2 FY27 revenue was ₹4,968.21 million, versus ₹4,291.91 million a year earlier; profit for the period was ₹754.83 million.

• Q2 reported EBITDA was ₹134.9 crore (+23.9% YoY), while PAT was ₹75.5 crore (+42.7%).

• H1 reported EBITDA margin expanded 190 bps to 26.2%; PAT margin rose 200 bps to 14.0%.

• Mid-teen H1 revenue growth was delivered without price increases, supported by demand and higher patient and test volumes.

Outlook and guidance

• Management expects H2 revenue growth and margin expansion to remain near H1 levels.

• Medium-term margin gains are supported by operating leverage, productivity, lab-platform transition and technology initiatives.

• Selective B2C price revisions are under evaluation; FY27 CapEx is expected at ₹65–70 crore.